Diagnostics-World
Twitter   LinkedIn Facebookinstagram RSS  
a-divisiion-of-chi
  • Subscribe
  • News
    • Latest News
    • Post a Press Release
    • View Press Releases
    • Submit a Story
    • Reprint Articles
  • Advertise
    • Media Kit
    • Digital Advertising Opportunities
    • Lead Generation
    • Whitepapers
    • Webinars
    • Podcasts
    • Editorial Calender
  • Free Downloads
    • Whitepapers
    • Podcasts
    • Webinars
    • Inside Ebooks
  • Events
    • Webinars
    • Industry Events
    • Dx Conferences
    • Tri-Conference
    • Next Generation Dx
    • Dx Innovation Summit
  • About
    • Editorial Profile
    • Editorial Calender
    • Contact
  • Molecular Med Tri-Conference
 
  • The Uneven Peace Between Medicare and Molecular Diagnostics

    Diagnostics World | Medicare, the single largest payer for healthcare in the United States, has a hodgepodge of national and state policies capable of bankrupting innovation in molecular diagnostics. It is an inequitable, fiscally perplexing, needlessly verbose, and fraud-prone system but, if there’s a bright spot, it’s the Molecular Diagnostic Services Program (MolDX) responsible for technology assessments and claims disbursement for more than half the country.

    Sep 5, 2023
  • Illumina, Pillar Announce Partnership, Clinical Care Assay Released, New Tech, Methods Developed, More

    Diagnostics World | Illumina and Pillar partner up to make Pillar’s oncology assays commercially available on a global scale; C2N Diagnostics releases the PrecivityAD2 blood test, a clinical care assay that meets the standard of care with currently available PET scans and cerebrospinal fluid tests; University of Missouri researchers developed an innovative method using nanopores; more.

    Aug 31, 2023
  • Treating A Broad Range Of Diseases, Accelerating Antibody Discovery, Technology Platform for Cell Analysis, More

    Diagnostics World | ADARx Pharmaceuticals will use financing for treatment of a broad range of diseases; A-Alpha Bio plans to use Series A2 funding to accelerate antibody discovery and development for emerging biothreats, including HIV; Cytomos will scale-up market testing of its technology platform for cell analysis; more.

    Aug 30, 2023
  • Changes Afoot In The Regulatory Landscape For Companion Diagnostics

    Diagnostics World | The U.S. Food and Drug Administration (FDA) has been making moves signaling its intention to better align the regulatory framework for companion diagnostics (CDx) to what is happening in real-world clinical practice.

    Aug 24, 2023
  • Self-Reported Data From Home Testing Could Benefit Public Health Surveillance

    Diagnostics World | Public health agencies have grappled with a succession of data problems associated with the COVID-19 pandemic, most notably how to accurately track prevalence rates when people are self-testing in the privacy of their home and don’t necessarily need or want to report the results.

    Aug 23, 2023
  • ‘Swarm Learning’ Approach To Improving Care Of Colorectal Cancer Patients

    Diagnostics World | Over the next three years, researchers from across five universities in Germany will be using “swarm learning” on retrospective tissue samples to gain insights on the tumor biology of hereditary colorectal cancer (CRC).

    Aug 22, 2023
  • Demographics Matter Under New Diagnostic Paradigm For Breast Cancer

    Diagnostics World | In a surprising twist, researchers at Sanford Burnham Prebys have found that both age and sex may matter a great deal when it comes to the consequences of many types of cancer.

    Aug 16, 2023
  • Researchers Find Aspirin-Independent Lipid Signature Of Preeclampsia

    Diagnostics World | Researchers at the University of Virginia School of Medicine have identified early biomarkers linked to preeclampsia that could help OB/GYNs better understand which of their patients are at risk of developing the potentially deadly pregnancy complication and perhaps help get at why the condition occurs in the first place.

    Aug 15, 2023
  • Unique Sensor Chip Detects Misfolded Proteins Linked to Neurodegeneration

    Diagnostics World | Researchers at the Swiss Federal Institute of Technology Lausanne (EPFL) have developed a novel biosensing tool combining multiple advanced technologies that shows promise in detecting misfolded proteins indicative of neurodegenerative diseases such as Parkinson’s and Alzheimer’s.

    Aug 10, 2023
  • Liver-on-a-Chip and Liver Organoid Research: Recent Findings Pave the Way Toward New Drug and Diagnostic Possibilities

    Diagnostics World | The liver carries out a variety of complex roles ranging from secretion and storage to metabolism and detoxification, and researchers across the globe see the potential of using liver-on-a-chip and liver organoid technologies to improve our understanding of this organ and find better ways of diagnosing and treating the diseases and conditions that hinder its normal operation.

    Aug 9, 2023
  • Proteins In The Blood Hint At Biological Basis Of Long COVID-19

    Diagnostics World | A point-of-care (POC) diagnostic test for long COVID is under development that would be a godsend to the millions of Americans still suffering the health consequences of SARS-CoV-2 months after being infected.

    Aug 8, 2023
  • Researchers Close In On Protein Panel For Predicting Islet Autoimmunity

    Diagnostics World | A team of researchers from North America and Europe have identified a panel of 83 markers in the blood of children genetically predisposed to develop type 1 diabetes that looks promising as a predictor of which individuals will progress to islet autoimmunity six months prior to its onset.

    Aug 3, 2023
  • Using ML to Diagnose Chronic Kidney Disease in a Bias-Free, Privacy-Protecting, Physician-Friendly Manner

    Diagnostics World | Carenostics is a healthcare AI startup founded with the mission of addressing the underdiagnosis, undertreatment, and health inequities of chronic disease using AI and ML on existing healthcare data.

    Aug 2, 2023
  • Consumer-Initiated Genetic Test from Quest Diagnostics, Collaboration to Understand Disease Molecules, New Facilities Opened

    Diagnostics World | Quest Diagnostics has launched its first consumer-initiated genetic test, the Allen Institute for Immunology and Eli Lilly and Company will collaborate to better understand disease molecules, and Cleveland Diagnostics opened a new facility for further prostate cancer testing. Plus, new partnerships and products from Lifebit, Allen Institute for Neural Dynamics, Critical Path Institute, and more.

    Jul 27, 2023
  • Follow the Money: AI Platform for Acute Immune States, Acquisitions, Expanding Solutions Portfolio

    Diagnostics World | AI platform used for acute immune states, acquisitions, solutions portfolio expansion, and more.

    Jul 26, 2023
  • An AI Tool for Lung Cancer Diagnosis in Indian Populations, Settings

    Diagnostics World | The prognosis of lung carcinoma has changed since the discovery of molecular targets and their specific drugs. Somatic EGFR mutations have been reported in lung carcinoma, and these mutant proteins act as substrates for targeted therapies.

    Jul 25, 2023
  • Continuous Stress Hormone Monitoring Takes Microdialysis To Whole New Level

    Diagnostics World | The dynamics of hormone secretion over the course of a day have largely been a mystery, and at the cost of delayed disease detection that often translates into bad odds for optimal recovery.

    Jul 20, 2023
  • Lab-On-A-Chip Device Taking On One Of The Biggest Diseases Of Poverty

    Diagnostics World | Capturing tuberculosis (TB) bacilli in a sputum sample can be like finding a needle in a haystack, unless the bacterial load is high. That’s when most cases are currently detected in low- and middle-income countries (LMICs) around the world.

    Jul 18, 2023
  • European Commission Levies Record Fines on Illumina, GRAIL Merger

    Diagnostics World | The European Commission announced this morning that it has fined Illumina and GRAIL approximately €432 million and €1,000 respectively—both record fines—for implementing their proposed merger before approval by the Commission, in breach of EU merger control rules.

    Jul 12, 2023
  • «
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18 (current)
  • 19
  • 20
  • »
 
CHI | Cambridge HealthTech Institute

250 First Avenue, Suite 300
Needham, MA 02494

P: 781.972.5400
F: 781.972.5425
E: chi@healthtech.com

Life Science Portals

Biological Therapeutic Products

Biomarkers & Diagnostics

Biopharma Strategy

Bioprocess & Manufacturing

Chemistry

Clinical Trials &
Translational Medicine

Drug & Device Safety

Drug Discovery & Development

Drug Targets

Healthcare

IT, AI, ML & Informatics

Technology & Tools For
Life Science

Therapeutic Indications

Venture, Innovation & Partnering

CHI Divisions

Conferences

Reports & Market Research

News & Advertising

Professional Services

Corporate Information

Cambridge Innovation
Institute

Executive Team

Testimonials

Mailing List

Careers


Request Information

Privacy Policy